🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Iniparib

    Sanofi Pasteur

    Breast Cancer, Metastatic

    phase 2 small molecule completed

    1 trial

  2. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  3. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  4. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  5. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Iodine-124

    United Therapeutics Europe Ltd

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  7. Iparomlimab/Tuvonralimab

    The First People's Hospital of Lianyungang

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  8. Iparomlimab/Tuvonralimab

    Chinese University of Hong Kong

    LOCALLY ADVANCED CERVICAL CANCERS

    phase 2 small molecule active

    1 trial

  9. Irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL , IRINOTECAN , Fluorouracil Hikma 50 mg/ml Injektionslösung, Ribofolin® 10 mg/ml Injektionslösung, JNJ-61186372, OXALIPLATIN , CALCIUM FOLINATE , JNJ-61186372, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    Janssen-Cilag International N.V.

    Advanced or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Irinotecan Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. Irofulven

    Allarity Therapeutics

    Metastatic Castration-Resistant Prostate Cancer Patients

    phase 2 small molecule completed

    1 trial

  13. Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  14. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  15. Ivonescimab

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    3 trials

  16. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  17. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  18. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  19. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  20. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  21. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  22. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  23. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  24. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources